Abstract: A method of inhibiting scale in a subterranean formation comprises pretreating the subterranean formation with a polyquaternary amine that serves as a squeeze life extension (SLE) agent, and then introducing a scale inhibitor pill into the subterranean formation, wherein the scale inhibitor pill includes one or more scale inhibitor compositions. For example, the polyquaternary amine may be a polymer having up to 5 quaternary amine centers, but is preferably a nonpolymeric diquaternary amine having a molecular weight of from 250 to 500. One such example is 1,3-propandiaminium, 2-hydroxy-N,N,N,N?,N?,N?-hexamethyl-, dichloride. The SLE agent is preferably introduced into the formation in a brine solution having a concentration from 0.1 to 20 weight percent. The SLE agents may be used with a variety of known scale inhibitors and scale inhibitor chemistries.

Abstract: A method of inhibiting scale in a subterranean formation comprises pretreating the subterranean formation with a polyquaternary amine that serves as a squeeze life extension (SLE) agent, and then introducing a scale inhibitor pill into the subterranean formation, wherein the scale inhibitor pill includes one or more scale inhibitor compositions. For example, the polyquaternary amine may be a polymer having up to 5 quaternary amine centers, but is preferably a nonpolymeric diquaternary amine having a molecular weight of from 250 to 500. One such example is 1,3-propandiaminium, 2-hydroxy-N,N,N,N?,N?,N?-hexamethyl-, dichloride. The SLE agent is preferably introduced into the formation in a brine solution having a concentration from 0.1 to 20 weight percent. The SLE agents may be used with a variety of known scale inhibitors and scale inhibitor chemistries.

Abstract: A method of inhibiting scale in a subterranean formation comprises pretreating the subterranean formation with a polyquaternary amine that serves as a squeeze life extention (SLE) agent, and then introducing a scale inhibitor pill into the subterranean formation, wherein the scale inhibitor pill includes one or more scale inhibitor compositions. For example, the polyquaternary amine may be a polymer having up to 5 quaternary amine centers, but is preferably a nonpolymeric diquaternary amine having a molecular weight of from 250 to 500. One such example is 1,3-propandiaminium, 2-hydroxy-N,N,N,N?,N?,N?-hexamethyl-, dichloride. The SLE agent is preferably introduced into the formation in a brine solution having a concentration from 0.1 to 20 weight percent. The SLE agents may be used with a variety of known scale inhibitors and scale inhibitor chemistries.

Abstract: A method of inhibiting scale in a subterranean formation comprises pretreating the subterranean formation with a polyquaternary amine that serves as a squeeze life extention (SLE) agent, and then introducing a scale inhibitor pill into the subterranean formation, wherein the scale inhibitor pill includes one or more scale inhibitor compositions. For example, the polyquaternary amine may be a polymer having up to 5 quaternary amine centers, but is preferably a nonpolymeric diquaternary amine having a molecular weight of from 250 to 500. One such example is 1,3-propandiaminium, 2-hydroxy-N,N,N,N?,N?,N?-hexamethyl-, dichloride. The SLE agent is preferably introduced into the formation in a brine solution having a concentration from 0.1 to 20 weight percent. The SLE agents may be used with a variety of known scale inhibitors and scale inhibitor chemistries.

Abstract: A treatment fluid for a subterranean formation includes a carrier fluid and an amount of particles including a granular scale inhibitor. The carrier fluid includes a hydratable gel fluid, a crosslinked gel fluid, an acid-based fluid, an oil-based fluid, and/or a visco-elastic surfactant. The particles include a proppant impregnated with the scale inhibitor, a solid particle formed largely from the scale inhibitor, or both. The proppant includes scale inhibitor adsorbed on porous surfaces within the proppant, and/or a porous proppant with scale inhibitor embedded in the bulk porosity of the proppant. The scale inhibitor is present in an amount between about 1% and 5% of a total weight of particles. The particles include scale inhibitor at a sufficient concentration and dissolution rate to provide acceptable scale inhibitor concentrations in produced fluids for production volumes exceeding 500 pore volumes.